PROCEPT BioRobotics Corporation (PRCT) saw its stock price surge 11.56% in night session trading on Thursday, following the release of its first-quarter 2026 financial results after market close on Wednesday.

The surgical robotics company reported quarterly revenue of $83.132 million, beating analyst estimates of $80.506 million and representing a 20% year-over-year increase. Adjusted EBITDA loss of $18.122 million also came in better than the expected $18.7 million loss, driven by strong U.S. system sales, improved pricing, and a 30% increase in U.S. procedures.

Investors reacted positively to the company's maintained full-year 2026 guidance, which projects revenue growth of 27% to 33%, and to the recent FDA clearance of its second-generation FirstAssist AI software for Aquablation therapy, which enhances the capabilities of its HYDROS robotic system. The combination of better-than-expected quarterly results and confidence in future growth prospects fueled the significant price movement.